TONTARRA MEDIZINTECHNIK acquired by RANTUM CAPITAL
Context
Rantum Private Equity Fund II has successfully finalized the acquisition of a majority stake in the share capital of the target, marking its seventh investment from the current fund. This strategic transaction represents a pivotal step in the acquirer’s objective to establish a dominant position in the high-precision medical technology sector, specifically targeting the resilient demand for minimally invasive surgery. The strategic rationale for the move centers on the high degree of alignment between the target’s fully integrated German manufacturing capabilities and the acquirer’s focus on high-moat, regulatory-intensive industrial platforms. By partnering with the founding family during a structured transition phase, the acquirer aims to professionalize the management framework and accelerate international market penetration. The partnership is designed to leverage the acquirer’s financial depth to drive targeted investments in product innovation and further certifications. This integration facilitates the scaling of the target’s proprietary brand while reinforcing its status as a mission-critical CDMO partner for global MedTech giants. This move solidifies the group’s standing as a primary enabler of technological modernization in the surgical instrument market.
TONTARRA MEDIZINTECHNIK, which reported an EBITDA margin of in 2026, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (15.6x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Tontarra is a premier technology organization specializing in the development and manufacturing of high-precision surgical instruments for both open and minimally invasive surgery. The entity’s business model is structured as a dual-track platform, maintaining a proprietary brand of patent-protected devices alongside a high-tier contract development and manufacturing (CDMO) service for global MedTech OEMs. Its value proposition is anchored in technical operational depth across the full value chain, from initial precision engineering and material manipulation to complex regulatory approval processes. Strategically, the firm focuses on the industrialization of endoscopy and microsurgical products, leveraging its fully integrated production facility within the globally recognized Tuttlingen medical technology cluster. By providing mission-critical hardware that meets extreme tolerance requirements, the organization ensures a vital role in modern clinical environments. The entity prioritizes innovation-led growth to address the rising global demand for specialized interventional procedures.
Ent. Value
Equity Value
Multiples
EV / Revenue
EV / EBITDA
EV / EBIT
Historical Financials (EUR)
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 06/2026 | BRIDGEPOINT | OBAGI MEDICAL | UNITED STATES | Generics / Labs |
| 05/2026 | STRYKER | AMPLITUDE VASCULAR SYSTEMS | UNITED STATES | Medical Devices |
| 04/2026 | DEVYSER DIAGNOSTICS | CYBERGENE | SWEDEN | Diagnostic Equipment |
| 04/2026 | OURY MEDICAL | CÉFIMÉCA | FRANCE | Implants & Prosthetics |
| 04/2026 | ASTORG | THERMO FISHER MICROBIOLOGY | UNITED STATES | Diagnostic Equipment |
| 04/2026 | FOR TALENTS / UI INVESTISSEMENT / GENEO | NEFTYS PHARMA | FRANCE | Animal Health |
| 04/2026 | FINE FOODS & PHARMACEUTICALS | SOFAR | ITALY | CDMO |
| 04/2026 | Gilead Sciences | Arcellx | UNITED STATES | R&D Biotech |
| 04/2026 | UCB | NEURONA THERAPEUTICS | UNITED STATES | R&D Biotech |
| 04/2026 | VITREX MEDICAL GROUP | HERNIAMESH | ITALY | Implants & Prosthetics |
REFERENCES
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of TONTARRA MEDIZINTECHNIK by RANTUM CAPITAL are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Press release: view release
Acquirer: rantum capital